{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lee J"],"funding":["Biomedical Research Institute grant, Kyungpook National University Hospital"],"pagination":["2087"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12467862"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(9)"],"pubmed_abstract":["<b>Background</b>: Breast cancer, particularly the luminal subtype, often responds to endocrine therapies. However, 20-30% of patients develop resistance, resulting in more aggressive disease. Long non-coding RNAs (lncRNAs) are implicated in cancer progression and treatment resistance. <b>Objective</b>: This study aimed to evaluate the role of the lncRNA insulin-like growth factor 2 antisense (IGF2-AS) in tamoxifen-resistant breast cancer and assess its potential as a therapeutic target. <b>Methods</b>: Two tamoxifen-resistant breast cancer cell lines (TAMR-V and TAMR-H) were used to assess IGF2-AS expression via qPCR. Knockdown experiments with siRNA evaluated the role of IGF2-AS in cell proliferation, invasion, and migration. Next-generation sequencing (NGS) analyzed gene expression differences between the cell lines. Kaplan-Meier survival analysis determined the clinical significance of IGF2-AS expression in breast cancer patients. <b>Results</b>: IGF2-AS expression was significantly upregulated in TAMR-V and TAMR-H cell lines compared to control MCF-7 cells. Knockdown of IGF2-AS reduced cell proliferation and invasion in TAMR-V cells but did not significantly affect TAMR-H cells, indicating a cell line-specific role in tamoxifen resistance. NGS revealed differential gene expression profiles between TAMR-V and TAMR-H cells, suggesting variability in resistance mechanisms. Survival analysis demonstrated that higher IGF2-AS expression was associated with poorer prognosis in breast cancer patients, including those with hormone-positive and triple-negative subtypes. <b>Conclusions</b>: IGF2-AS is upregulated in tamoxifen-resistant breast cancer and promotes cell proliferation and invasion in a cell line-specific manner. Its differential expression in TAMR-V and TAMR-H cells highlights the complexity of resistance mechanisms, suggesting IGF2-AS as a potential therapeutic target for overcoming tamoxifen resistance."],"journal":["Biomedicines"],"pubmed_title":["Differential Expression of Long Non-Coding RNA IGF2-AS in Tamoxifen-Resistant Breast Cancer Cells."],"pmcid":["PMC12467862"],"funding_grant_id":["2021"],"pubmed_authors":["Park NJ","Kang B","Lee SJ","Park JY","Park HY","Lee J","Kim EA","Jung JH","Kang J","Lee IH","Chae YS"],"additional_accession":[]},"is_claimable":false,"name":"Differential Expression of Long Non-Coding RNA IGF2-AS in Tamoxifen-Resistant Breast Cancer Cells.","description":"<b>Background</b>: Breast cancer, particularly the luminal subtype, often responds to endocrine therapies. However, 20-30% of patients develop resistance, resulting in more aggressive disease. Long non-coding RNAs (lncRNAs) are implicated in cancer progression and treatment resistance. <b>Objective</b>: This study aimed to evaluate the role of the lncRNA insulin-like growth factor 2 antisense (IGF2-AS) in tamoxifen-resistant breast cancer and assess its potential as a therapeutic target. <b>Methods</b>: Two tamoxifen-resistant breast cancer cell lines (TAMR-V and TAMR-H) were used to assess IGF2-AS expression via qPCR. Knockdown experiments with siRNA evaluated the role of IGF2-AS in cell proliferation, invasion, and migration. Next-generation sequencing (NGS) analyzed gene expression differences between the cell lines. Kaplan-Meier survival analysis determined the clinical significance of IGF2-AS expression in breast cancer patients. <b>Results</b>: IGF2-AS expression was significantly upregulated in TAMR-V and TAMR-H cell lines compared to control MCF-7 cells. Knockdown of IGF2-AS reduced cell proliferation and invasion in TAMR-V cells but did not significantly affect TAMR-H cells, indicating a cell line-specific role in tamoxifen resistance. NGS revealed differential gene expression profiles between TAMR-V and TAMR-H cells, suggesting variability in resistance mechanisms. Survival analysis demonstrated that higher IGF2-AS expression was associated with poorer prognosis in breast cancer patients, including those with hormone-positive and triple-negative subtypes. <b>Conclusions</b>: IGF2-AS is upregulated in tamoxifen-resistant breast cancer and promotes cell proliferation and invasion in a cell line-specific manner. Its differential expression in TAMR-V and TAMR-H cells highlights the complexity of resistance mechanisms, suggesting IGF2-AS as a potential therapeutic target for overcoming tamoxifen resistance.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-05-02T03:18:43.411Z","creation":"2026-05-02T03:11:49.464Z"},"accession":"S-EPMC12467862","cross_references":{"pubmed":["41007650"],"doi":["10.3390/biomedicines13092087"]}}